Treatment, not delivery, of the late preterm and term fetus with supraventricular arrhythmia

Author:

Holmes S.1ORCID,Hornberger L. K.2,Jaeggi E.3ORCID,Howley L.4ORCID,Moon‐Grady A. J.5,Uzun O.6,Kaizer A.7,Gilicze O.5,Cuneo B. F.18ORCID

Affiliation:

1. The Heart Institute, Children's Hospital Colorado University of Colorado Aurora CO USA

2. Division of Cardiology, Department of Pediatrics, Stollery Children's Hospital University of Alberta Edmonton AB Canada

3. Division of Cardiology, Department of Pediatrics, Hospital for Sick Children University of Toronto Toronto ON Canada

4. Children's Hospital Minnesota Minneapolis MN USA

5. University of California San Francisco San Francisco CA USA

6. School of Medicine and University Hospital of Wales Cardiff UK

7. Department of Biostatistics and Informatics University of Colorado Aurora CO USA

8. Colorado Fetal Care Center, Children's Hospital Colorado University of Colorado Aurora CO USA

Abstract

ABSTRACTObjectiveWhile in‐utero treatment of sustained fetal supraventricular arrhythmia (SVA) is standard practice in the previable and preterm fetus, data are limited on best practice for late preterm (34 + 0 to 36 + 6 weeks), early term (37 + 0 to 38 + 6 weeks) and term (> 39 weeks) fetuses with SVA. We reviewed the delivery and postnatal outcomes of fetuses at ≥ 35 weeks of gestation undergoing treatment rather than immediate delivery.MethodsThis was a retrospective case series of fetuses presenting at ≥ 35 weeks of gestation with sustained SVA and treated transplacentally at six institutions between 2012 and 2022. Data were collected on gestational age at presentation and delivery, SVA diagnosis (short ventriculoatrial (VA) tachycardia, long VA tachycardia or atrial flutter), type of antiarrhythmic medication used, interval between treatment and conversion to sinus rhythm and postnatal SVA recurrence.ResultsOverall, 37 fetuses presented at a median gestational age of 35.7 (range, 35.0–39.7) weeks with short VA tachycardia (n = 20), long VA tachycardia (n = 7) or atrial flutter (n = 10). Four (11%) fetuses were hydropic. In‐utero treatment led to restoration of sinus rhythm in 35 (95%) fetuses at a median of 2 (range, 1–17) days; this included three of the four fetuses with hydrops. Antiarrhythmic medications included flecainide (n = 11), digoxin (n = 7), sotalol (n = 11) and dual therapy (n = 8). Neonates were liveborn at 36–41 weeks via spontaneous vaginal delivery (23/37 (62%)) or Cesarean delivery (14/37 (38%)). Cesarean delivery was indicated for fetal SVA in two fetuses, atrial ectopy or sinus bradycardia in three fetuses and obstetric reasons in nine fetuses that were in sinus rhythm at the time of delivery. Twenty‐one (57%) cases were treated for recurrent SVA after birth.ConclusionIn‐utero treatment of the near term and term (≥ 35‐week) SVA fetus is highly successful even in the presence of hydrops, with the majority of cases delivered vaginally closer to term, thereby avoiding unnecessary Cesarean section. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.

Publisher

Wiley

Subject

Obstetrics and Gynecology,Radiology, Nuclear Medicine and imaging,Reproductive Medicine,General Medicine,Radiological and Ultrasound Technology

Reference24 articles.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3